Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BOLT NASDAQ:CNTB NASDAQ:KNTE NYSE:VOR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBOLTBolt Biotherapeutics$5.29-1.5%$5.48$4.59▼$14.36$10.31M0.98,306 shs9,067 shsCNTBConnect Biopharma$1.61$1.90$0.51▼$2.86$89.71M-0.09137,056 shs56,347 shsKNTEKinnate Biopharma$2.65$2.61$1.04▼$7.18$125.13M1.38418,678 shsN/AVORVor Biopharma$1.52$2.04$0.13▼$3.29$192.56M2.057.58 million shs4.73 million shs10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBOLTBolt Biotherapeutics-1.49%+1.24%+8.62%-8.64%-57.46%CNTBConnect Biopharma-2.07%-1.23%-11.05%+56.31%+38.79%KNTEKinnate Biopharma0.00%0.00%0.00%0.00%0.00%VORVor Biopharma0.00%-16.25%-25.85%+532.54%+62.71%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBOLTBolt Biotherapeutics$5.29-1.5%$5.48$4.59▼$14.36$10.31M0.98,306 shs9,067 shsCNTBConnect Biopharma$1.61$1.90$0.51▼$2.86$89.71M-0.09137,056 shs56,347 shsKNTEKinnate Biopharma$2.65$2.61$1.04▼$7.18$125.13M1.38418,678 shsN/AVORVor Biopharma$1.52$2.04$0.13▼$3.29$192.56M2.057.58 million shs4.73 million shs10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBOLTBolt Biotherapeutics-1.49%+1.24%+8.62%-8.64%-57.46%CNTBConnect Biopharma-2.07%-1.23%-11.05%+56.31%+38.79%KNTEKinnate Biopharma0.00%0.00%0.00%0.00%0.00%VORVor Biopharma0.00%-16.25%-25.85%+532.54%+62.71%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBOLTBolt Biotherapeutics 2.33Hold$47.50797.92% UpsideCNTBConnect Biopharma 3.50Strong Buy$7.00334.78% UpsideKNTEKinnate Biopharma 0.00N/AN/AN/AVORVor Biopharma 2.56Moderate Buy$6.07299.12% UpsideCurrent Analyst Ratings BreakdownLatest VOR, CNTB, BOLT, OXB, and KNTE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/15/2025BOLTBolt BiotherapeuticsLake Street CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$75.008/14/2025VORVor BiopharmaHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$3.008/13/2025CNTBConnect BiopharmaHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$7.007/22/2025CNTBConnect BiopharmaNorthland CapmkSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy6/30/2025VORVor BiopharmaHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeNeutral ➝ Buy$3.006/26/2025VORVor BiopharmaWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral ➝ Outperform(Data available from 9/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBOLTBolt Biotherapeutics$4.17M2.44N/AN/A$29.89 per share0.18CNTBConnect Biopharma$26.03M3.45N/AN/A$1.67 per share0.96KNTEKinnate BiopharmaN/AN/AN/AN/A$5.06 per shareN/AVORVor BiopharmaN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBOLTBolt Biotherapeutics-$63.12M-$26.66N/AN/AN/AN/A-91.67%-53.19%11/11/2025 (Estimated)CNTBConnect Biopharma-$15.63MN/A0.00N/AN/AN/AN/AN/AN/AKNTEKinnate Biopharma-$116.27M-$2.78N/AN/AN/AN/A-62.31%-54.72%N/AVORVor BiopharmaN/A-$13.66N/AN/AN/AN/AN/AN/AN/ALatest VOR, CNTB, BOLT, OXB, and KNTE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025BOLTBolt Biotherapeutics-$6.40-$4.46+$1.94-$4.46$0.82 million$1.80 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBOLTBolt Biotherapeutics$0.366.81%N/AN/A N/ACNTBConnect BiopharmaN/AN/AN/AN/AN/AKNTEKinnate BiopharmaN/AN/AN/AN/AN/AVORVor BiopharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBOLTBolt Biotherapeutics0.563.113.11CNTBConnect Biopharma0.017.247.24KNTEKinnate BiopharmaN/A10.8010.80VORVor BiopharmaN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBOLTBolt Biotherapeutics86.70%CNTBConnect Biopharma58.72%KNTEKinnate Biopharma80.89%VORVor Biopharma97.29%Insider OwnershipCompanyInsider OwnershipBOLTBolt Biotherapeutics6.10%CNTBConnect Biopharma22.60%KNTEKinnate Biopharma41.70%VORVor Biopharma0.45%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBOLTBolt Biotherapeutics901.92 million1.80 millionNot OptionableCNTBConnect Biopharma11055.72 million43.13 millionOptionableKNTEKinnate Biopharma8447.22 million27.53 millionOptionableVORVor Biopharma140126.68 million65.45 millionNot OptionableVOR, CNTB, BOLT, OXB, and KNTE HeadlinesRecent News About These CompaniesVor Biopharma trading halted on Thursday, news pending2 hours ago | msn.comVor Biopharma trading halted, news pending2 hours ago | msn.comVor Biopharma Inc. (NYSE:VOR) Given Consensus Recommendation of "Moderate Buy" by BrokeragesSeptember 18 at 2:30 AM | marketbeat.comHead to Head Survey: Prime Medicine (NASDAQ:PRME) versus Vor Biopharma (NYSE:VOR)September 18 at 2:45 AM | americanbankingnews.comResults of China Phase III Clinical Study of Telitacicept for Generalized Myasthenia Gravis Selected for Oral Presentation at 2025 AANEM Annual MeetingSeptember 17 at 9:00 PM | prnewswire.comVor Bio Announces Oral Presentation of 48-Week China Phase 3 Generalized Myasthenia Gravis Clinical Study at AANEMSeptember 17 at 4:15 PM | globenewswire.comReprogrammed Interchange Llc Sells 284,805 Shares of Vor Biopharma (NYSE:VOR) StockSeptember 16 at 8:27 PM | marketbeat.comVor Biopharma (NYSE:VOR) Major Shareholder Sells $525,000.00 in StockSeptember 16 at 8:27 PM | marketbeat.comVor Biopharma (NYSE:VOR) Major Shareholder Sells $656,000.00 in StockSeptember 16 at 8:27 PM | marketbeat.comVor Biopharma (NYSE:VOR) Major Shareholder Reprogrammed Interchange Llc Sells 284,805 SharesSeptember 16 at 4:33 AM | insidertrades.comInsider Selling: Vor Biopharma (NYSE:VOR) Major Shareholder Sells 464,421 Shares of StockSeptember 12, 2025 | marketbeat.comReprogrammed Interchange Llc Sells 350,000 Shares of Vor Biopharma (NYSE:VOR) StockSeptember 12, 2025 | marketbeat.comReprogrammed Interchange Llc Sells 449,226 Shares of Vor Biopharma (NYSE:VOR) StockSeptember 12, 2025 | marketbeat.comVor Bio to Participate in the Stifel 2025 Virtual Immunology and Inflammation ForumSeptember 12, 2025 | globenewswire.comInsider Selling: Vor Biopharma (NYSE:VOR) Major Shareholder Sells 350,000 Shares of StockSeptember 11, 2025 | insidertrades.comWe Think Vor Biopharma (NASDAQ:VOR) Needs To Drive Business Growth CarefullySeptember 7, 2025 | finance.yahoo.comOMERS ADMINISTRATION Corp Takes Position in Vor Biopharma Inc. $VORSeptember 7, 2025 | marketbeat.comVor Bio Appoints Adi Osovsky, S.J.D. as General CounselSeptember 2, 2025 | globenewswire.comInsider Selling: Vor Biopharma (NYSE:VOR) Major Shareholder Sells 611,647 Shares of StockAugust 30, 2025 | insidertrades.comVor Biopharma (NYSE:VOR) Major Shareholder Reprogrammed Interchange Llc Sells 284,190 SharesAugust 28, 2025 | insidertrades.comVor Biopharma shares rise after collaborator’s IgAN therapy meets Phase 3 endpointAugust 28, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All Headlines3 Robotics Stocks at the Heart of the Robotics RevolutionBy Chris Markoch | August 21, 2025Big Analyst Revisions Could Be Ahead for SoFi StockBy Gabriel Osorio-Mazilli | August 26, 2025Shopify’s Risk-Reward Profile Is Suddenly Red HotBy Sam Quirke | August 22, 2025The Most Upgraded Stocks in Q3: Good News for the S&P 500By Thomas Hughes | September 17, 2025Why Seagate Is Wall Street's New Favorite AI Infrastructure PlayBy Jeffrey Neal Johnson | September 18, 2025VOR, CNTB, BOLT, OXB, and KNTE Company DescriptionsBolt Biotherapeutics NASDAQ:BOLT$5.29 -0.08 (-1.49%) Closing price 09/18/2025 04:00 PM EasternExtended Trading$5.16 -0.13 (-2.44%) As of 09/18/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company's lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer. It is also developing BDC-3042, an agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer. The company has collaboration agreements with Toray Industries, Genmab A/S, Innovent Biologics, Inc., Bristol-Myers Squibb, and F. Hoffmann-La Roche Ltd; and license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California.Connect Biopharma NASDAQ:CNTB$1.61 0.00 (0.00%) Closing price 09/18/2025 04:00 PM EasternExtended Trading$1.60 -0.02 (-0.93%) As of 08:41 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets. Its lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis and asthma, currently under Phase 3 studies; and icanbelimod (formerly CBP-307), an oral small molecule Sphingosine 1-Phosphate Receptor 1 modulator, currently under Phase 2 clinical for the treatment of ulcerative colitis and Crohn's disease. The company was founded in 2012 and is based in San Diego, California.Kinnate Biopharma NASDAQ:KNTEKinnate Biopharma Inc., a clinical-stage oncology company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; KIN-3248 small-molecule kinase inhibitors that target cancer-associated alterations in fibroblast growth factor receptors FGFR2 and FGFR3 genes; and small molecule research programs, including Cyclin-Dependent Kinase 12(CDK12) inhibitor in its KIN004 program. The company was incorporated in 2018 and is headquartered in San Francisco, California. Kinnate Biopharma Inc. is a former subsidiary of Fount Therapeutics, LLC.Vor Biopharma NYSE:VOR$1.52 0.00 (0.00%) Closing price 09/18/2025 04:00 PM EasternExtended Trading$1.53 +0.01 (+0.66%) As of 09/18/2025 07:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Vor Biopharma Inc. operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies. The company is also developing Mylotarg, a CD33-directed antibody drug conjugate (ADC) therapy for patients with leukemia; VCAR33, a CAR-T therapy designed to target CD33, a clinically validated target for AML, which are under preclinical and Phase 1/2 clinical studies; trem-cel + VCAR33 treatment system that is under preclinical studies for the treatment of AML; and CD33-CLL1 treatment system made with CD33-CLL1 multiplex-engineered eHSC and CD33-CLL1 multi-specific CAR-T, which are under preclinical studies for the treatment of AML. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The Fed Cut Rates: What Now for the S&P 500 and Equity Markets? Joby's Stock Is Quiet, But Its Commercial Engine Is In Overdrive Eli Lilly’s Oral GLP-1 Breakthrough Could Change Everything Bloom Energy Booms on AI Power Demand and Analyst Upgrades Can Apple’s iPhone 17 and AI Push Its Stock to New Highs? Why Seagate Is Wall Street's New Favorite AI Infrastructure Play New Catalysts Build Positive Pressure on Intel Stock Oracle to Hit $1 Trillion Valuation in 2025: Here’s Why Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
